GPs are using artificial intelligence to record patient consultations but how safe is your personal data?
His intern is completely digital. It is an artificial intelligence scribe that listens to every word his patients say.
"It's mostly surprisingly accurate," the GP told 7.30.
"Occasionally it will mishear the name of something. Occasionally it will mishear a diagnosis."
He says patient consent when using AI scribes in a clinical setting is essential but that most people don't have an issue.
"I do ask for consent. Occasionally people don't want me to use it, which is absolutely fine, but almost everyone is comfortable with it and it just streamlines the work," Dr Blashki said.
"It's good for the patient because I'm concentrating on them."
Dr Blashki says he has become so reliant on the scribe that he would struggle to conduct appointments without it.
"I use it almost in every consultation," he said.
As patients reveal intimate details about their medical history with Dr Blashki, he says the scribe is constantly collecting sensitive data.
"So I make sure that at the end of each consultation I actually delete all the transcriptions off my software."
Dr Blashki uses software from Melbourne-based company Heidi Health, which is one of the main AI scribe tools used by clinicians in Australia.
Heidi Health declined 7.30's request for an interview but its CEO and co-founder Dr Thomas Kelly provided a written response to questions about patient privacy.
"Heidi now supports almost two million visits a week, and that's around the world from Australia, New Zealand, Canada, to the US and the UK," Dr Kelly said.
"In each region, data is stored in compliance with the healthcare regulations and privacy policies of the region."
"Here it's Australian Privacy Principles (APP), in the EU that would be GDPR, in the US that would be HIPAA. All data is protected according to ISO 27K and SOC2 requirements, which are the highest enterprise standards that exist. We get audited by third parties to protect our data and ensure the security that we have.'
Dr Kelly says all data is protected according to "the highest enterprise standards that exist".
Lyrebird Health is another AI scribe software company that is based in Melbourne.
It is used by GPs, surgeons, psychiatrists and paediatricians — the company says the software was used in "200,000 consults" in Australia last week.
"All data is stored 100 per cent in Australian sovereign databases if you're an Australian customer — it's different obviously if you're overseas," Lyrebird Health CEO Kai Van Lieshout told 7.30.
Patient notes are deleted automatically after seven days from Lyrebird Health's system (doctors need to back up the notes if they want to keep them), but users do have the option to manually extend this period to six months.
"For us it is definitely really gone," Mr Van Lieshout said.
"I know that because we've had doctors that have needed something that we've had ... that don't realise that it's deleted after seven days and there's nothing we can do."
John Lalor is an Assistant Professor of IT, Analytics and Operations at the University of Notre Dame, he warns there is always an element of risk when storing digital data.
"A lot of those models, they're very data-driven, so the more data they have, usually the better they get," Mr Lalor told 7.30.
"So on the one hand, if it has a lot more data from patients, that can typically improve the models, but on the other hand, there's the privacy risk of the data being exposed if it's leaked or hacked."
He says patients and doctors should be making sure AI scribe companies are transparent with how they are storing and using data.
"Making sure that the firms are clear with how exactly the data is being used, because if there's ambiguity in what they say, then there could be ambiguity in the interpretation as well," he said.
"With individuals, if they're uncomfortable with using something like that, they could speak with their physician to see if it's optional or see if they could get more information about what exactly is being done when the data is taken into scribe system."
To show how Heidi Health's AI scribe works, Dr Blashki has taken 7.30 through a mock appointment about a headache.
We discuss how the headache has been "on and off pretty much every morning for the last month" and that there's no history of migraines.
Heidi Health then processes the conversation, in a process it calls 'Making Magic', then produces consultation notes.
The software also suggests "differential diagnoses" including a "tension-type headache" and a "cervicogenic headache".
"We're seeing some of the medical softwares and some of the AI generally come up with differential diagnoses, make suggestions, and ... the doctor really needs to turn their mind to it and look at them more as suggestions than the answer," Dr Blashki said.
Dr Kelly said the software "aims to be more than a literal summary and is able to identify the clinical rationale underpinning a line of questioning".
In response to 7.30's mock consultation, Dr Kelly said: "We summarise the clinical encounter reflecting their lines of questioning and using appropriate clinical terminology to describe them.
Mr Van Lieshout said Lyrebird Health doesn't produce potential diagnoses after a consultation.
"We won't try to tell the clinician what to do, if that makes sense," he said.
"It's subjective to: what did the patient describe? Did I do any forms of examination? What was their blood pressure assessment? What's my diagnosis or assessment of situation? Then plan what's the next steps.
"We will break up that conversation into those categories."
Dr Blashki said about 50 per cent of the doctors in the GP clinic he works at in Melbourne are using AI scribe software for every consultation.
He says he has also received referral letters from specialists that look like they've been created by AI.
"I have had one letter where I think, 'Oh, I don't think they've checked this properly. They've clearly got one of the diagnoses not quite right'," he said.
Former Victorian Chief Health Officer Brett Sutton believes AI scribes have become "indispensable" although he conceded that protecting patient data is the greatest concern for the industry.
"I think the regulators need to make sure that it's safe," Dr Sutton said.
"Obviously the clinicians who are using it have a responsibility for sensitive health information to be properly recorded and stored and made safe, so that it's treated in exactly the same way as any other clinical notes would be treated historically."
Watch 7.30, Mondays to Thursdays 7:30pm on ABC iview and ABC TV
Do you know more about this story? Get in touch with 7.30 here.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

ABC News
an hour ago
- ABC News
Creatine supplements can be effective but experts warn against gummies and dodgy marketing
"If you have a body you can benefit from it." "If you're not taking it, you're missing out." These are just some of the claims about creatine that social media is awash with. As Brisbane based sports dietitian Taryn Richardson says, "creatine is having a real moment". Hype around taking creatine supplements is at an all-time high and there's never been more product options on the market; from cola gummies to "icy blue razz" powders that are mixed with a drink. Creatine is a compound naturally produced by the body and also found in animal-based products like fish and meat. It's found in most muscles in the body, as well as the brain, and used as a source of energy to allow muscles to flex. Our bodies make around half the creatine we need each day (about 2 to 4 grams) but the rest has to come from the food we eat or supplementation. Creatine is one of the most studied supplements and there is extensive evidence it can support muscle growth and improve athletic performance. Emerging research shows it might even help our brains. But some experts are urging consumers to do some research before they buy. "There's this messaging at the moment that everyone should take creatine supplements no matter who they are and what they're doing, and I really disagree with that," Ms Richardson said. Some brands are selling "premium" types of creatine that don't have adequate scientific backing but customers are paying more for them, according to experts. "Just remember these supplement companies have really good marketing teams," said Professor Matthew Cooke, a nutritionist at La Trobe University, who has done extensive research on creatine. There's also "femvertising" of some products with pretty, pink packaging, collagen add-ins and female-centric marketing, with one US brand even calling themselves "Sheatine". Then there's the gummies. Creatine gummies are advertised as a delicious and easy-to-take option but independent testing has repeatedly shown some contain almost zero creatine. One popular brand sold in Australia called PUSH was forced to halt all sales after testing showed their gummies were significantly underdosed with creatine. Sydney-based personal trainer James Smith was skeptical about the gummy products and whether they met their label claims so he sent nine brands for testing at independent lab Eurofins. All of the testing was made public and only one brand, Wellboost's strawberry banana gummies, contained the advertised 5 grams of creatine. PUSH's strawberry flavour gummies returned a creatine reading of 0.102 grams per serving when it should have been 5 grams. Their apple flavour came in at 0.112 grams. PUSH was charging $59.95 for a 30-day supply. Anaesthetic technician Tina Hill had been taking PUSH gummies for four months before learning they were just "expensive lollies". "I was just throwing money down the drain," she said. Ms Hill said she heard about creatine online and wanted to support her strength training but was also interested in any potential cognitive benefits it could give her. "I saw all of those well-known fitness influencers who had come from a competitive background were promoting PUSH gummies on social media and it seemed reliable," she said. In a statement, PUSH told the ABC it accepted full responsibility for the underdosing and was now suing its former manufacturer. PUSH has accused the manufacturer, which is based in China, of altering the product formula without their knowledge. "Production is now underway with a new Australian based manufacturer to strengthen quality control and prevent issues like this from happening again," PUSH said. "Moving forward every batch of PUSH gummies will be independently tested by Eurofins US." But experts say consumers should avoid all creatine gummies brands for now. "I think these companies have good intentions but it comes down to the production — with the process of making gummies such as heating likely decreasing the levels of creatine," Professor Cooke said. Ms Richardson agreed. "For now I'm telling my clients to stick with powders — they are a lot cheaper anyway," she said. Ms Hill switched to a powder supplement and said she is finally feeling the effects of creatine. "A few weeks in I do feel like I've seen a huge improvement in my fitness levels and just my general wellbeing." Women generally have lower levels of creatine as they tend to get a lower intake through their diet and have lower muscle mass than men, which means they have lower creatine storage. Studies have also shown vegetarians and vegans have lower baseline levels. "A lot of us probably aren't getting enough creatine from our diet as we're heading towards more plant-based diets or at least reducing the amount of meat we eat," Professor Cooke said. Evidence shows creatine supplementation can boost the total creatine in your muscles by around 20 to 40 per cent. Some people do this quickly by starting with a "loading" phase of 20 grams per day for a week and then lowering to 5 grams per day. Loading isn't necessary though, Professor Cooke said, because you get the same results by starting at 5 grams per day, it will just take a bit longer. For most people it will result in more power and strength for explosive bursts of exercise and it improves recovery after exercise-related muscle damage as well as sarcopenia (loss of muscle as we age) if taken in conjunction with resistance training. Recently, researchers started delving deeper into the potential benefits of creatine among women and how it might assist during hormonal fluctuations. During menopause, estrogen and progesterone levels decline significantly which may negatively impact creatine metabolism so supplementation could be beneficial at this time, Professor Cooke said. Research has shown creatine supplementation can help post-menopausal women with physical function when combined with resistance training and now experts want to explore how it might support bone health during perimenopause when bone density starts to decrease. It's early days but research is also suggesting supplementation may benefit pre-menopausal women during their menstrual cycles when there's varying levels of creatine metabolism and fatigue. Some brands are now shamelessly trying to capture the female market by using taglines like "craft your perfect peach" or advertising "creatine for women" when it's exactly the same as the "genderless" creatine on the market. Professor Cooke said some brands may be capitalising on the recent research that's been more focused on women. "I know some marketing will take advantage of this but in the research space it's really great to see this research in the female population." Creatine is mostly stored in muscles but a small amount is also found in the brain and there's evidence it may benefit mood and cognitive function, particularly for those who are sleep deprived. It could even help with recovery from traumatic brain injuries. More high-quality research is needed but some studies show it could potentially help people with Alzheimer's disease. Jose Antonio is a professor of health and human performance at Nova Southeastern University in Florida and said he was particularly excited by the neuroscience research into creatine. "Even if you don't care about the muscular strength side of things I tell my students they should take it for their brain because in the last five years there's been more data showing it can help with cognitive processes," Professor Antonio said. It's worth nothing though that approximately 20 to 30 per cent of people are non-responders to creatine supplementation, meaning that they see little to no benefit from it. Creatine can be bought in a few different forms and the vast majority of research is on creatine monohydrate (creatine molecule + water molecule). But some brands are selling new formulations in which they bond the creatine molecule to other compounds to make: Many brands selling these claim they are up to five times more effective or better absorbed than creatine monohydrate. "That's baloney," Professor Jose Antonio said, "not only are they more expensive, they don't work better. "Some of them claim, 'this is better absorbed than creatine monohydrate' but monohydrate is 99.9 per cent absorbed so you're not going to get any better absorption." Professor Cooke said some of these may actually be less effective and he wouldn't recommend buying anything other than creatine monohydrate. Creatine supplements are safe and have limited side effects — some people may experience some bloating but that can generally be minimised by taking a lower dose or taking it with meals. But Ms Richardson doesn't recommend heading straight to the supplement aisle saying a "food first" approach is best. "There's no point adding sprinkles to the cake if you don't have your cake baked first — you need to build a foundation of good day-to-day nutrition through your diet and only then would I look to add supplements to that." Professor Cooke said taking a creatine supplement was personal preference but he is glad it's no longer seen as something just for "gym heads". "I think the key thing here is it's safe and there's benefits across the life span."

Sydney Morning Herald
an hour ago
- Sydney Morning Herald
Nvidia supercomputer marks ‘new era' for Australian AI
Nvidia, the world's most valuable company, is teaming with Monash University and Dell to build an Australia-first supercomputer that promises to elevate the country into the AI big leagues. The supercomputer, dubbed MAVERIC and built in collaboration with CDC Data Centres, will be purpose-built for large-scale AI and data-intensive workloads and feature technology never before deployed in the country. MAVERIC will be housed at CDC's facility in the Melbourne suburb of Brooklyn, with construction to begin later this year. The system is expected to go live in early 2026, and was the subject of a meeting between Australia's ambassador to the US Kevin Rudd, Assistant Minister for Science Andrew Charlton and Nvidia executives on Wednesday morning. 'Without this kind of AI super-computer power, Australian researchers are trying to compete on the world stage with one arm tied behind their back,' Monash University vice-chancellor Sharon Pickering said in an interview. 'We are making a $60 million investment here so that Australia can be world leaders, and not just be willing to take second place. We have to be willing to be the best in the world and for our world-leading researchers; my job is to get them the best infrastructure in the world to support them.' MAVERIC will initially focus on advancing medical research, Pickering said, including developing new pharmaceutical products and personalising treatments for patients suffering from acute medical conditions. It will also focus on environmental issues including a study of the Antarctic and research into the impact of heat on populations. It will be available to university researchers and academics, students and research partners. The supercomputer will be built using Dell racks and servers and feature Nvidia's GB200 NVL72 platform. Amid debate about Australia's role in the global AI arms race, Dell Australia managing director Angela Fox said that MAVERIC represented a 'leapfrogging' opportunity for the nation in its AI capabilities. 'It allows researchers to use increasingly sophisticated AI models to tackle some of Australia and the world's most pressing issues and will deliver lasting value for the nation,' she said. 'It's a massive win for the research community and for Australia as a whole.'

The Age
an hour ago
- The Age
Nvidia supercomputer marks ‘new era' for Australian AI
Nvidia, the world's most valuable company, is teaming with Monash University and Dell to build an Australia-first supercomputer that promises to elevate the country into the AI big leagues. The supercomputer, dubbed MAVERIC and built in collaboration with CDC Data Centres, will be purpose-built for large-scale AI and data-intensive workloads and feature technology never before deployed in the country. MAVERIC will be housed at CDC's facility in the Melbourne suburb of Brooklyn, with construction to begin later this year. The system is expected to go live in early 2026, and was the subject of a meeting between Australia's ambassador to the US Kevin Rudd, Assistant Minister for Science Andrew Charlton and Nvidia executives on Wednesday morning. 'Without this kind of AI super-computer power, Australian researchers are trying to compete on the world stage with one arm tied behind their back,' Monash University vice-chancellor Sharon Pickering said in an interview. 'We are making a $60 million investment here so that Australia can be world leaders, and not just be willing to take second place. We have to be willing to be the best in the world and for our world-leading researchers; my job is to get them the best infrastructure in the world to support them.' MAVERIC will initially focus on advancing medical research, Pickering said, including developing new pharmaceutical products and personalising treatments for patients suffering from acute medical conditions. It will also focus on environmental issues including a study of the Antarctic and research into the impact of heat on populations. It will be available to university researchers and academics, students and research partners. The supercomputer will be built using Dell racks and servers and feature Nvidia's GB200 NVL72 platform. Amid debate about Australia's role in the global AI arms race, Dell Australia managing director Angela Fox said that MAVERIC represented a 'leapfrogging' opportunity for the nation in its AI capabilities. 'It allows researchers to use increasingly sophisticated AI models to tackle some of Australia and the world's most pressing issues and will deliver lasting value for the nation,' she said. 'It's a massive win for the research community and for Australia as a whole.'